Safety and Tolerability of Weekly Semaglutide 0.5 mg or 1.0 mg in Chilean Subjects With Type 2 Diabetes
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 104
- 试验地点
- 3
- 主要终点
- Number of Adverse Events (AEs)
研究概览
简要总结
This study is testing the safety and tolerability of subcutaneous semaglutide in participants with type 2 diabetes (T2D) in Chile. Participants will get a once-weekly subcutaneous injection of semaglutide in doses decided by the study doctor's criteria, according to participant's personal needs. The study will last for about 24 weeks. Participants will have 4 clinic visits and 2 phone calls. Participants will have 3 laboratory tests during the study (blood and urine samples).
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Participants diagnosed (clinically) with type 2 diabetes greater than equal to (≥) 90 days prior to the screening visit.
- •Stable daily dose of Oral Antidiabetic Drug (OAD) and/or insulin treatment for ≥ 60 days prior to the screening visit.
- •HbA1c 7.5-10% (59-86 millimoles per mole [mmol/mol]) (both inclusive) in Visit
- •Participants in which Ozempic is indicated according to approved local label.
- •Fundoscopy/Fundus photography record less than equal to (≤) 12 months.
排除标准
- •Known or suspected hypersensitivity to study intervention(s) or related products.
- •Previous participation in this study. Participation is defined as signed informed consent.
- •Female who is pregnant, breast-feeding or intends to become pregnant or is of childbearing potential and not using adequate contraceptive method.
- •Participation in any clinical trial of an approved or non-approved investigational medicinal product within 30 days before the screening visit, except Coronavirus Disease 2019 (COVID-19) related trials (this is allowed).
- •Treatment with any glucagon-like peptide-1 receptor agonists (GLP-1 RA) medication prior to the screening visit.
- •Any disorder which in the investigator's opinion might jeopardise participant's safety or compliance with the protocol.
- •Family or personal history of Multiple Endocrine Neoplasia Type 2 or Medullary Thyroid Carcinoma.
- •History of pancreatitis (acute or chronic).
- •Renal impairment defined as estimated glomerular filtration rate (eGFR) below 30 milliliters/minute (mL/min)/1.73 meter square (m^2) as per MDRD-4 (Modification of Diet in Renal Disease).
- •Myocardial infarction, stroke or hospitalisation for unstable angina or transient ischaemic attack within the past 180 days prior to the day of screening.
- •Participants presently classified as being in New York Heart Association (NYHA) Class IV heart failure.
- •Planned coronary, carotid or peripheral artery revascularisation known on the day of screening.
- •Participants with alanine aminotransferase (ALT) > 2.5 x upper normal limit (UNL).
- •Use of systemic immunosuppressive treatment within 90 days prior to screening.
- •Treatment with any medication for the indication of diabetes or obesity other than stated in the inclusion criteria in a period of 90 days before the day of screening. An exception is short-term insulin treatment for acute illness for a total of ≤ 14 days.
- •Known hypoglycaemic unawareness and/or recurrent severe hypoglycaemic episodes as judged by the investigator.
- •Proliferative retinopathy or maculopathy requiring acute treatment. Verified by fundus photography or dilated fundoscopy performed within 12 months prior to screening.
- •History or presence of malignant neoplasms within the last 5 years (except basal and squamous cell skin cancer and carcinoma in situ).
研究组 & 干预措施
Semaglutide
Participants will receive semaglutide subcutaneous (s.c.) injection once weekly in a dose escalation manner for 24 weeks: 0.25 milligrams (mg) (weeks 1 to 4), 0.5 mg (weeks 5 to 12) and 0.5 mg or 1.0 mg (weeks 13 to 24).
干预措施: Semaglutide (Drug)
结局指标
主要结局
Number of Adverse Events (AEs)
时间窗: From baseline (Day 1) up to 24 weeks
Number of adverse events from baseline (Day 1) to week 24 is presented. An adverse event is any untoward medical occurrence in a clinical study participant that is temporally associated with the use of investigational medicinal product (IMP), whether or not considered related to the IMP. The outcome measure was evaluated based on the data from on-treatment observation period which was defined as sub-set of the 'in-trial' observation period and represents the time period where participants are considered exposed to study product. The observation period ends at the first date of any of the following: follow-up visit, premature discontinuation follow-up visit, last date on study product + 42 days for safety and +7 days for efficacy, end-date for the 'in-trial' observation period.
次要结局
- Participants Achieving Greater Than or Equal (≥) 10% Weight Reduction (Yes/No)(From baseline (week 1) to week 24)
- Change in Total Cholesterol (mg/dL)(Baseline (week 1), week 24)
- Change in Low Density Lipoprotein (LDL) Cholesterol (mg/dL)(Baseline (week 1), week 24)
- Change in High Density Lipoprotein (HDL) Cholesterol (mg/dL)(Baseline (week 1), week 24)
- Change in Triglycerides (mg/dL)(Baseline (week 1), week 24)
- Change in Estimated Glomerular Filtration Rate (eGFR) [Millilitre Per Minute (mL/Min) Per 1.73 Square Meter (m^2)](Baseline (week 1), week 24)
- Change in Urine Albumin-Creatinine Ratio (UACR) [Milligram Per Gram (mg/g)](Baseline (week 1), week 24)
- Participants Discontinued Due to Adverse Events (Treatment Discontinuation)(From baseline (week 1) to week 24)
- Number of Severe or Blood Glucose Confirmed Symptomatic Hypoglycaemic Episodes(From baseline (week 1) to week 24)
- Change in Glycosylated Haemoglobin (HbA1c)(Baseline (week 1), week 24)
- Participants Achieving HbA1c Less Than (<) 7.0 Percentage (%) [Yes/No](From baseline (week 1) to week 24)
- Change in Fasting Plasma Glucose (FPG) [Milligrams Per Decilitre (mg/dL)](Baseline (week 1), week 24)
- Change in Body Weight (Kilogram [Kg])(Baseline (week 1), week 24)
- Change in Waist Circumference [Centimeter (cm)](Baseline (week 1), week 24)
- Participants Achieving Greater Than or Equal (≥) 5% Weight Reduction (Yes/No)(From baseline (week 1) to week 24)
- Number of Severe Hypoglycaemic Episodes(From baseline (week 1) to week 24)
- Number of Serious Adverse Events (SAEs)(From baseline (week 1) to week 24)
- Number of Adverse Reactions (ARs)(From baseline (week 1) to week 24)
- Number of Serious Adverse Reactions (SARs)(From baseline (week 1) to week 24)
- Number of Suspected Unexpected Serious Adverse Reactions (SUSARs) Per Participant(From baseline (week 1) to week 24)
- Change From Baseline in Heart Rate (Pulse) After 24 Weeks of Treatment(Baseline (week 1), week 24)